Skip to main content
. 2011 Jan 19;31(6):1412–1423. doi: 10.1038/jcbfm.2010.230

Figure 3.

Figure 3

Low-dose, prolonged treatment with deferoxamine (DFO) does not induce erythropoietin (EPO) or vascular endothelial growth factor (VEGF) protein abundance in brain as measured by enzyme-linked immunosorbent assay (ELISA) (two-way analysis of variance (ANOVA) with Bonferroni's posttest analysis, n=3 mice in each group).